Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Baton who wrote (12848)	7/14/2003 8:40:00 AM
From: Crossy	Respond to of 48461

Baton, the fundamentals of this company do support a target price in the mid teens, maybe more midterm.. I'm not the "hit and run" type as many traders here. I am looking for multibaggers. Fact is when I looked at SDAY at first I could hardly believe the valuation.. great I pressed the button CROSSY

To: Baton who wrote (12848)	7/14/2003 9:29:32 AM
From: Bucky Katt	Respond to of 48461

ARIA, our $1.50 rat baby, should make a new 52w high today on this news> ARIAD Research Highlights Beneficial Profile of Its Promising Product to Treat Cancer That Has Spread to Bone Lead Story in American Association for Cancer Research Press Release CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 14, 2003-- ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA - News) announced, for the first time on Saturday at the American Association for Cancer Research press briefing on the efficacy of novel cancer treatments, results of pre-clinical studies demonstrating the potential therapeutic benefits of its product candidate to treat cancer that has spread to bone. AP23841 combines, in a single small-molecule drug, effective blockade of both tumor growth and bone destruction - the two processes that need to be controlled to treat the grave clinical consequences of bone metastases. Of the more than 5000 abstracts that were submitted for presentation to the 94th annual meeting of the AACR, three were featured in its press release entitled "New generation of treatments show promise for cancer patients: Studies show combined therapies, new targets effective in fighting disease." The lead story in the AACR release was ARIAD's product candidate to treat cancer in bone.